Nihon Hinyokika Gakkai zasshi. The japanese journal of urology最新文献

{"title":"[EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].","authors":"Kiyoaki Nishihara, Hirofumi Kurose, Naoki Ito, Satoshi Ohnishi, Taishi Hirano, Hiroki Suekane, Kouta Watanabe, Katsuaki Chikui, Kosuke Ueda, Kei-Ichiro Uemura, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa","doi":"10.5980/jpnjurol.115.21","DOIUrl":"10.5980/jpnjurol.115.21","url":null,"abstract":"<p><p>(Purpose) Enfortumab vedotin has been available as a third-line treatment for advanced urothelial carcinoma in Japan since December 2021. While the treatment is expected to improve the outcome of advanced urothelial carcinoma, concerns regarding adverse events do exist. We report here our initial experience of the use of enfortumab vedotin as a third-line therapy in patients with advanced urothelial carcinoma. (Patients and Methods) We retrospectively evaluated the efficacy and adverse events of enfortumab vedotin treatment, as a third line therapy, in patients who had failed platinum-containing chemotherapy and immune checkpoint inhibitor therapy in our institution from January 2022 to January 2023. Efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and duration of response (DOR). Safety was evaluated for treatment-related adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0. (Results) In this study, sixteen patients were investigated. The median age was 70 years (45-93 years); all patients had previously received platinum-containing chemotherapy with cisplatin or carboplatin, eleven having been treated with pembrolizumab, and 5 with avelumab, as sequential immune checkpoint inhibitors. As for efficacy, the median observation period was 9.27 months (4.03-16.6 months). The treatment response rate included 2 complete response (CR) (12.5%), 5 partial response (PR) (31.3%), and 5 stable disease (SD), out of 16 patients. The ORR and DCR were 43.8% and 75.0%, respectively. The median PFS was 7.77 months (3.67-not reached). The median time to response was 1.87 months (0.47-2.80 months) and the median DOR was 7.93 months (0.73-13.1 months). Eight patients (50%) discontinued treatment due to disease progression. As for safety, the incidence of treatment-related adverse events (TRAE) was 93.8%, and that of Grade 3 or higher TRAE was 56.3%. Four out of 16 patients (25%) underwent dose reduction due to TRAE. Among all grades, skin reactions were the most common in 12 patients (75%), followed by dysgeusia, alopecia, neutropenia, and anorexia. Neutropenia (including febrile neutropenia) was the most common Grade 3 or higher TRAE in five patients (31.3%), followed by skin reactions, anorexia, and anemia. Two of the patients, who observed skin reactions, developed severe rash and Stevens-Johnson syndrome, which eventually led to treatment discontinuation. The median time from enfortumab vedotin administration to onset of skin reaction was 9 days (5-18 days), with most cases occurring in the first cycle. (Conclusions) Enfortumab vedotin is an effective treatment option in real clinical practice. However, adverse events, including skin reactions, should be carefully monitored.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 1","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[CLINICAL EVALUATION OF THERAPEUTIC EFFECT PREDICTORS IN PEMBROLIZUMAB FOR ADVANCED UROTHELIAL CANCER].","authors":"Yoshitaka Itami, Chihiro Omori, Motokiyo Yoshikawa, Takeshi Inoue, Yoshiaki Matsumura, Katsuya Aoki, Yoriaki Kagebayashi","doi":"10.5980/jpnjurol.115.1","DOIUrl":"10.5980/jpnjurol.115.1","url":null,"abstract":"<p><p>(Purpose) We performed a clinical retrospective study on the evaluation of pembrolizumab treatment results for advanced urothelial cancer in our hospital. (Materials and Methods) Twenty-seven patients diagnosed with advanced or metastatic urothelial carcinoma who received pembrolizumab between April 2018 and December 2021 were included. We retrospectively reviewed medical records to examine treatment outcomes, immune-related adverse event (irAE), and prognostic factors. (Results) The median age of patients was 76 years, and the median number of pembrolizumab doses was 6. The median overall survival was 8.8 months, and the best treatment response according to RECIST version 1.1 was complete response 1, partial response 7, stable disease 5, and progression disease 14. Pre-pembrolizumab risk factors related to overall survival include the presence of liver metastasis, LDH ≥200 IU/L, and TSH <4 μIU/mL in univariate analysis. Grade 3 irAE was type 1 diabetes in only 1 case, and grade 2 were hypothyroidism in 4 cases, type 1 diabetes in 1 case, interstitial pneumonia in 1 case, and skin disorder in 1 case. Nine patients had a TSH of 4 μIU/mL or higher at the start of pembrolizumab, and four of them had hypothyroidism requiring oral levothyroxine, and none of the patients in the low TSH group required hormone replacement (p =0.013). (Conclusion) High TSH level before pembrolizumab administration for advanced urothelial cancer was associated with hypothyroidism, suggesting the possibility of improved prognosis.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A CASE OF RENAL HILAR TUMORS IN IGG4-RELATED DISEASE].","authors":"Koichiro Uehara, Yosuke Shibata, Kota Washimi, Kimito Osaka","doi":"10.5980/jpnjurol.115.134","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.134","url":null,"abstract":"<p><p>A 72-year-old man was referred to our hospital because of right renal tumors. Ultrasound examination revealed two masses in the right renal hilum. Contrast-enhanced computed tomography (CT) scan showed 25 mm and 10 mm soft tissue density nodules with poor contrast effect in the right renal hilum. Positron emission tomography-CT scan showed an accumulation of SUVmax of 6.65 in the same area. A CT-guided biopsy was performed, and immunostaining revealed the presence of IgG4-positive plasma cell clusters and a high serum IgG4 level of 658 mg/dL. A definitive diagnosis of IgG4-related disease was made, and the patient was placed under observation.A CT-guided biopsy is helpful for the diagnosis of IgG4-related disease and should be considered when masses are found in the unilateral renal hilum.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 3","pages":"134-137"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[BLADDER OUTLET OBSTRUCTION (SUSPICIOUS FOR FOWLER'S SYNDROME) IN A WOMAN IN HER FORTIES: A CASE REPORT].","authors":"Sakiko Teramoto, Nagayuki Kurosawa, Hiroki Ito, Shingo Nagai, Yasuyuki Kubota","doi":"10.5980/jpnjurol.115.124","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.124","url":null,"abstract":"<p><p>Dysuria is caused by bladder outlet obstruction (BOO) and detrusor underactivity. Female BOO is often overlooked because it is difficult to diagnose a condition from history and symptoms alone. Fowler's syndrome is seen in young women and causes urinary retention due to a primary disorder of urethral sphincter relaxation. Although the level of evidence is still low, sacral neuromodulation or intra-sphincteric Botulinum toxin injection has been applied to Fowler's syndrome. A 44-year-old woman with a chief complaint of dysuria started clean intermittent catheterization because of urinary retention. Videourodynamics showed BOO, open bladder neck, and narrowing of the middle urethra during voiding, and MRI showed thickening of the urethral sphincter. A neurological examination was performed with no neurologic features, so the diagnosis of Fowler's syndrome was suggested. The possibility of a diagnosis of female BOO should always be kept in mind when a woman has dysuria, and urodynamic study or Videourodynamics should be considered.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 3","pages":"124-127"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[SUCCESSFUL PRESERVATION OF TORSED TESTICLE USING TUNICA ALBUGINEA INCISION: REPORT OF TWO CASES].","authors":"Kazuro Kikkawa, Yuko Ueda, Yasuo Kohjimoto, Isao Hara","doi":"10.5980/jpnjurol.115.85","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.85","url":null,"abstract":"<p><p>Testicular torsion is a condition of ischemia due to blood flow disturbance, ischemia-reperfusion injury after the detorsion, and compartment syndrome with increased intratesticular pressure. If no improvement in testicular color and appearance is noted after the detorsion, the tunica albuginea incision can be performed to preserve the testis. Case 1: A 13-year-old male came to our hospital with left scrotal pain, and emergency surgery was performed six hours after the onset with the diagnosis of left testicular torsion. The left testis was externally rotated 180 degrees, and the testis remained poorly colored after the detorsion. The testicular color improved after the tunica albuginea incision. The defect of the albuginea was covered with a tunica vaginalis flap. One year after the operation, testicular size remained the same, and blood flow in the left testis was good. Case 2: A 16-year-old male came to our hospital with right scrotal pain, and emergency surgery was performed 10 hours after the onset with a diagnosis of right testicular torsion. The right testicle was internally rotated 180 degrees, and the testis remained poorly colored after the detorsion. The tunica albuginea incision was performed and covered with a tunica vaginalis flap after improvement of color. Six months after the operation, testicular size remained the same, and blood flow in the right testis was good. Testicular preservation was possible with tunica albuginea incision and tunica vaginalis flap for testicular torsion. However, the long-term effect of these techniques on testicular function is unclear, and long-term follow-up is likely to be necessary.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 2","pages":"85-89"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[SUCCESSFUL TREATMENT WITH mFOLFOX6 FOR URACHAL ADENOCARCINOMA WITH MULTIPLE LUNG METASTASIS: A CASE REPORT].","authors":"Rumiko Sugimura, Tadashi Tabei, Yuta Karibe, Takahiro Mitomi, Hiroki Takizawa, Makoto Funahashi, Junichi Ota","doi":"10.5980/jpnjurol.115.28","DOIUrl":"10.5980/jpnjurol.115.28","url":null,"abstract":"<p><p>We report the case of a 41-year-old man who presented with gross hematuria and a bladder tumor on ultrasonography. Magnetic resonance imaging indicated a possible muscle-invasive bladder cancer or urachal carcinoma. Following transurethral resection of the bladder tumor, histopathological findings revealed an adenocarcinoma similar to colorectal cancer. The patient was diagnosed with an urachal carcinoma in the urinary bladder dome. Since multiple lung metastases were observed on computed tomography, and his serum carcinoembryonic antigen level was 116 ng/dL, his final diagnosis was a stage IVb urachal carcinoma. He received 11 courses of mFOLOX6, and underwent a laparoscopy-assisted partial cystectomy and pelvic lymph node dissection. Pathological examination confirmed negative surgical margins, but remained tumor cells were confirmed. The patient continued mFOLFOX6 treatment for 12 months postoperatively, with no disease progression observed.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 1","pages":"28-32"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A CASE OF TESTICULAR TUMOR UNDER CONSIDERATION FOR PARTIAL ORCHIECTOMY THROUGH RAPID INTRAOPERATIVE DIAGNOSIS].","authors":"Jurii Karibe, Teppei Takeshima, Takashi Kawahara, Eren Iwasa, Takayuki Hirano, Yushi Araki, Daiji Takamoto, Hiroaki Ishida, Kimito Osaka, Jun-Ichi Teranishi, Yasushi Yumura, Hiroji Uemura","doi":"10.5980/jpnjurol.115.33","DOIUrl":"10.5980/jpnjurol.115.33","url":null,"abstract":"<p><p>A 35-year-old man visited a local doctor for continuing analysis of his infertility. Semen analysis revealed azoospermia while an ultrasonography detected a right testicular tumor with a diameter of 10 mm. A blood test was negative for tumor markers. Magnetic resonance imaging showed a 1-cm tumor in the right testis and atrophy of the left testis. A testicular tumor arising from a functional unilateral testis was discovered during infertility treatment for which the patient was referred to our hospital for fertility preservation. Right and left testicular volumes were 18 mL and 3 mL, respectively, and his serum testosterone level was 2.96 ng/mL. Noting the atrophy of the contralateral testicle, we proceeded with a rapid pathology diagnosis by partial testicular resection. If no evidence of tumor malignancy was found, the surgery would have been concluded with no further dissection. Since the patient was undergoing fertility treatment, the decision was made to take sperm from the extracted testicle to preserve his fertility, followed by orchiectomy. Because a seminoma was suspected through the rapid pathological diagnosis, the man eventually underwent higher orchiectomy and testicular sperm extraction. The final diagnosis was seminoma, followed by successful retrieval of a sufficient level of sperm. Post operative serum testosterone level was found to be 0.32 ng/mL, after which testosterone replacement therapy was introduced. Through rapid diagnosis of pathology, successful management and outcome were achieved in the case of testicular cancer combined with infertility.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 1","pages":"33-36"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A CASE OF REFRACTORY BLADDER HEMORRHAGE AFTER GASTROCYSTOPLASTY].","authors":"Sho Yamagiwa, Hiroshi Yamada, Hiroko Morikami, Shigeki Ishiguro, Tomoyoshi Ohashi, Hideki Mizuno, Toshinori Nishikimi","doi":"10.5980/jpnjurol.115.90","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.90","url":null,"abstract":"<p><p>A 34-year-old man had undergone living donor kidney transplantation for hypoplastic and dysplastic kidney and gastrocystoplasty and umbilical-urinary tract reconstruction using the appendix for contracted bladder in his early childhood. At the age of 19 years, renal transplant function was lost, and hemodialysis was thus initiated. Since then, he had regularly visited our department while continuing to perform urethral self-catheterization and self-bladder irrigation to alleviate bladder irritation symptoms due to hematuria-dysuria syndrome. Subsequently, the patient experienced hemorrhage from the bladder augmented with the stomach, which led to the development of bladder tamponade and the progression of anemia. He was thus admitted to our department and received continuous bladder irrigation and other conservative therapies, as well as vascular embolization. Because hemostasis was not achieved despite these procedures, partial cystectomy (resection of the bladder augmented with the stomach) was performed. Here, we report our experience with a patient with refractory bladder hemorrhage due to hematuria-dysuria syndrome, for which we performed partial cystectomy and achieved hemostasis. Although gastrocystoplasty has been rarely performed in recent years because of specific postoperative complications such as hematuria-dysuria syndrome, caution should be exercised in patients with anuria due to renal failure or other causes.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 2","pages":"90-93"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A CASE OF PYELONEPHRITIS AND ILIOPSOAS ABSCESS EXTENDING TO THE THIGH DUE TO IMPACTED URETERAL STONE, TREATED IN COLLABORATION WITH AN ORTHOPEDIC SURGEON].","authors":"Yuta Suzuki, Masahiko Inahara, Miki Ishibashi, Tatsuo Igarashi, Shunji Kishida","doi":"10.5980/jpnjurol.115.128","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.128","url":null,"abstract":"<p><p>A 80-year-old woman presented with a swelling and pain in the left thigh visited our hospital. CT showed an impacted stone in the left ureter, left hydronephrosis and abscess formation extending from the perirenal area to the left thigh. Immediately, the patient was admitted and left nephrostomy was placed. On day 3 of admission, drainage of abscess in the left thigh was performed with the cooperation of an orthopedic surgeon. On day 17, a contrast-enhanced CT showed shrinkage of the thigh abscess, however, showed the left non-functioning kidney and poor drainage of the left iliopsoas abscess. On day 24, open left nephrectomy and unroofing of the iliopsoas abscess were performed, and all the abscess showed shrinkage thereafter. To sum up, multiple drainage should be considered for widely extending abscess originated in the retroperitoneal space.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 3","pages":"128-133"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[MINIMALLY INVASIVE SURGICAL TREATMENT WITH WATER VAPOR ENERGY THERAPY FOR LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA: A PROSPECTIVE STUDY].","authors":"Taiki Kato, Ryosuke Chaya, Teruaki Sugino, Yuya Ota, Kazumi Taguchi, Takashi Hamakawa, Yasue Kubota, Tetsuji Maruyama, Takahiro Yasui","doi":"10.5980/jpnjurol.115.116","DOIUrl":"https://doi.org/10.5980/jpnjurol.115.116","url":null,"abstract":"<p><p>(Introduction and objective) Water vapor energy therapy (WAVE) received insurance approval in Japan in September 2022 for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Here we report a prospective trial of WAVE. (Patients and methods) This study included 16 patients who underwent WAVE between November 2022 and December 2023. International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, overactive bladder symptom score, post-void residual urine volume (PVR), prostate volume (PV) measured using transrectal ultrasonography, postoperative catheter removal rate, surgical duration, and adverse events were recorded preoperatively and at 1, 3, 6, and 12 months postoperative. (Results) The median age was 76.5 years, and 11 of 16 patients (69%) received antiplatelets and/or anticoagulants. The median preoperative PV was 43.5 ml, while the median postoperative follow-up period was 6.9 months. Comparison of the baseline and 6-month postoperative follow-up values showed that the median IPSS and IPSS-QOL scores decreased significantly (by 48% and 55%, respectively), while the median PV was significantly reduced by 36%. The median PVR was reduced by 51%; however, the difference was not significant. Catheter removal was successful in 80% of patients. The median surgical duration was 8.5 min (range, 4.0-26.0 min). Complications (grade ≤ II) according to the Common Terminology Criteria for Adverse Events v5.0 occurred in 12 patients. (Conclusion) WAVE is a useful minimally invasive surgical approach in elderly patients and patients receiving antiplatelets and/or anticoagulants, featuring a short surgical duration, improved micturition, and no serious adverse events.</p>","PeriodicalId":101330,"journal":{"name":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology","volume":"115 3","pages":"116-123"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}